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ameliorates the degenerative pathology and
prevents demyelination in a model of multiple
system atrophy
Markus Mandler1†, Elvira Valera2†, Edward Rockenstein2, Michael Mante2, Harald Weninger1, Christina Patrick2,
Anthony Adame2, Sabine Schmidhuber1, Radmila Santic1, Achim Schneeberger1, Walter Schmidt1,
Frank Mattner1 and Eliezer Masliah2,3*Abstract
Background: Multiple system atrophy (MSA) is a neurodegenerative disease characterized by parkinsonism, ataxia
and dysautonomia. Histopathologically, the hallmark of MSA is the abnormal accumulation of alpha-synuclein (α-syn)
within oligodendroglial cells, leading to neuroinflammation, demyelination and neuronal death. Currently, there is no
disease-modifying treatment for MSA. In this sense, we have previously shown that next-generation active vaccination
technology with short peptides, AFFITOPEs®, was effective in two transgenic models of synucleinopathies at reducing
behavioral deficits, α-syn accumulation and inflammation.
Results: In this manuscript, we used the most effective AFFITOPE® (AFF 1) for immunizing MBP-α-syn transgenic mice,
a model of MSA that expresses α-syn in oligodendrocytes. Vaccination with AFF 1 resulted in the production of specific
anti-α-syn antibodies that crossed into the central nervous system and recognized α-syn aggregates within glial cells.
Active vaccination with AFF 1 resulted in decreased accumulation of α-syn, reduced demyelination in neocortex,
striatum and corpus callosum, and reduced neurodegeneration. Clearance of α-syn involved activation of microglia
and reduced spreading of α-syn to astroglial cells.
Conclusions: This study further validates the efficacy of vaccination with AFFITOPEs® for ameliorating the
neurodegenerative pathology in synucleinopathies.
Keywords: Multiple system atrophy, Active immunization, Immunotherapy, Alpha-synuclein, AFFITOPE®Background
Multiple system atrophy (MSA) is a progressive, neurode-
generative disease characterized by parkinsonism resistant
to dopamine therapy, ataxia, autonomic dysfunction, and
pathological accumulation of α-synuclein (α-syn) [1-4].
MSA differs from other synucleinopathies in that α-syn ac-
cumulates not only within neurons and astrocytes, but also
within oligodendrocytes in the form of glial cytoplasmic* Correspondence: emasliah@ucsd.edu
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unless otherwise stated.inclusions [5]. This intracellular accumulation of toxic α-
syn species leads to degeneration of oligodendroglial cells,
loss of trophic support to neurons and subsequent
neurodegeneration.
In recent years increasing evidence supports the notion
that α-syn is primarily generated by neurons, where it ag-
gregates and gets released to the extracellular environ-
ment [6,7]. Extracellular aggregated α-syn would then
propagate to other neurons and glial cells in a prion-like
fashion [8,9]. However, a recent report of MSA oligoden-
drocytes also expressing α-syn mRNA [10] suggests that
the origin of oligodendroglial α-syn might be both of en-
dogenous nature and the result of propagation from neu-
rons and/or other oligodendroglial cells. Furthermore,l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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could lead to activation of these cells and subsequent neu-
roinflammation [11-13]. Therefore, the development of
therapeutic interventions/strategies for MSA and related
neuropathologies has been focused on reducing α-syn ac-
cumulation, increasing α-syn clearance and/or inhibiting
α-syn propagation. One of these therapeutic alternatives is
immunotherapy.
To date there are no disease-modifying treatments for α-
synucleinopathies. The discovery that α-syn oligomers can
be secreted [14,15] and propagate extracellularly [16,17] pro-
vided a clear rationale for immunotherapy [18]. Humoral
immunization against α-syn can occur in one of two forms,
active or passive immunity [18]. Active immunization
involves stimulating the immune system to produce anti-
bodies against toxic α-syn conformations, while passive
immunization involves administering anti-α-syn antibodies
to the patient, which confers temporary protection against
the disease. Recent preclinical studies have been successful
in clearing intraneuronal α-syn aggregates and reducing
neuron-to-neuron α-syn propagation by immunotherapy,
focusing on stimulating or restoring the ability of the im-
mune system to fight the disease [18-22]. In this sense,
Phase 1 clinical trial is currently investigating the use of ac-
tive immunotherapy with PD01A for Parkinson’s disease
(PD), and intravenous immunoglobulins are being used in a
Phase 2 clinical trial for MSA.
Recent studies suggest that active immunotherapy in-
creases α-syn clearance and might be a viable therapy for
PD, a closely related neurodegenerative disease character-
ized by extensive α-syn deposition in neurons [19,20].
AFFiRiS has developed novel active immunogens (AFFI-
TOPEs®) that hold the promise of treating these disorders.
AFFITOPEs® are short immunogenic peptides that are too
short for inducing a T-cell response (autoimmunity) and
do not carry the native epitope but rather a sequence that
mimics the original epitope [23,24]. This methodology al-
lows for the generation of long term, sustained, more spe-
cific, non-cross reacting antibody responses suitable for
the treatment of synucleinopathies. The main objective of
this study was to evaluate the effects vaccination with the
AFFITOPE® proven most effective for PD models on redu-
cing the MSA-like pathology in the MBP-α-syn transgenic
(tg) mice [19].
Results
Titers and trafficking of AFF 1-induced antibodies into the
CNS in MBP-α-syn tg mice
For the analysis of the immunogenicity and efficacy of
AFFITOPE® vaccines in a MSA model, MBP-α-syn tg mice
were immunized six times at monthly intervals applying
conjugate vaccines containing either the AFFITOPE® AFF 1
(mimicking the C-terminus of α-syn) or the original C-
terminal α-syn peptide (α-syn 110–130) coupled to Keyholelimpet hemocyanin (KLH) as carrier and using alhydrogel
as adjuvant. As control condition MBP-α-syn tg mice were
immunized with the adjuvant alone. Levels of vaccine-
induced antibodies were assessed after each immunization
(Figure 1A-1D). Both immunogens (AFF 1 and the original
C-terminal α-syn peptide) were able to mount a compar-
able immune response against recombinant human α-syn
after three immunizations, thus demonstrating their similar
immunogenicities (Figure 1A). In contrast to the original
C-terminal α-syn peptide, AFF 1 failed to induce antibodies
that cross-react with murine α-syn (Figure 1A). Further-
more, the AFFITOPE® AFF 1 elicited similar antibody titers
against the immunizing peptide moiety as the original epi-
tope (Figure 1B and data not shown), but, in contrast to the
original α-syn peptide, failed to induce antibodies directed
against human β-synuclein (Figure 1B and data not shown).
To study the long-term immunologic responses of
AFFITOPE® vaccines in the MBP-α-syn tg model, an
analysis of the immune reaction over time was per-
formed assessing reactivity to the immunizing peptide
moiety and to human α-syn (Figure 1C, 1D). Titers of
antibodies against the peptide moiety of AFF 1 quickly
rose after a single immunization (Figure 1C), and
reached a plateau after the third immunization. In com-
parison, titers of antibodies directed against recombinant
human α-syn were slightly lower (Figure 1D).
After completion of the immunization protocol, the effi-
cacy of immunization was assessed by histological and
biochemical analysis. Immunohistochemical analysis of
brain sections from naïve non-tg, mThy1-α-syn tg, and
MBP-α-syn tg mice using sera from AFF 1-immunized an-
imals as primary antibody source confirmed that AFF 1-
induced antibodies detected intracellular and axonal ag-
gregates in the naïve tg mice but not in the non-tg animals
(Figure 1E). AFF 1-induced antibodies displayed reactivity
similar to the human α-syn-specific antibody LB509 in
this assay. No immunoreactivity was observed with sera
of mice immunized with a control vaccine (IgG). To
determine which species of α-syn the antibodies elicited
by AFF 1 immunization recognize, immunoblot analysis
was performed with monomeric and aggregated α-syn
(Figure 1F) using 4-hydroxy-2-nonenal [25]. This analysis
showed that AFF 1-induced antibodies detected oligomer-
ized α-syn as well as α-syn monomers. The human α-syn-
specific antibody LB509 was used as positive control.
In order to study the trafficking of AFF 1-induced anti-
bodies into the CNS, a monoclonal antibody derived from
an animal undergoing repeated AFF 1 immunization was
produced according to standard procedures [26], subse-
quently tagged with Alexa-488 and injected intravenously
into non-tg and MBP-α-syn tg mice (Figure 2A). Vibratome
brain sections were analyzed by confocal microscopy
48 h after injection. Only blood vessel labeling was ob-
served in the non-tg mice injected with the Alexa-488-
Figure 1 Titers, kinetics and reactivity of AFF 1-induced antibodies after repeated immunization in MBP-α-syn tg mice. (A) Titers
of antibodies against human and murine α-syn elicited after immunization with vehicle, original C-terminal α-syn antigen or AFF 1 (B) IgG
response towards the immunizing peptide AFF 1 (as BSA conjugate) as well as against recombinant human α-syn and β-syn from plasma taken
at end point (C) Kinetics of the IgG responses to the immunizing peptide following vaccination with vehicle or AFF 1 (D) Kinetics of the IgG
responses to recombinant human α-syn following vaccination with vehicle or AFF 1 (E) α-syn immune reactivity of AFF 1-induced antibodies in
brain sections of naïve non-tg, mThy1-α-syn tg and MBP-α-syn tg mice. Plasma from AFF 1-immunized MBP-α-syn tg mice was used at a final
dilution of 1:100. As positive control, the human α-syn-specific antibody LB509 was used. An anti-mouse IgG antibody was used as negative
control. Cell nuclei were stained with DAPI (blue) (F) Immunoblot analysis of AFF 1-induced antibodies against aggregated (o) and monomeric
(m) recombinant α-syn. The human α-syn-specific antibody LB509 was used as positive control. Aggregated (oligomeric) α-syn was obtained by
4-hydroxy-2-nonenal treatment. Titers are depicted as OD max/2 at 405 nm. PP, Preplasma; EP, end point plasma; P1-P5, plasma taken after each
immunization. For titer calculations, n = 10 animals per group.
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the MBP-α-syn tg mice injected with Alexa-488-tagged
mAb-AFF 1 showed binding to α-syn aggregates in the
neuropil and in cell bodies (Figure 2A), likely after a
process of antigen-antibody complex internalization
[20,27]. A non-immune IgG1 tagged with Alexa-488
was used as negative control, showing only labeling in
blood vessels.
Time-course analysis showed that the highest binding
level of the Alexa-488-tagged mAb-AFF 1 was observedafter 48 h, with a decline at 72 h (Figure 2C). To assess
which cell type internalized the AFF 1-induced antibodies
in the MBP-α-syn tg mice, we performed double immuno-
staining analysis applying an anti-mouse IgG1 and a neur-
onal (NeuN), astroglial (S100), microglial (Iba1) or
oligodendroglial antibody (p25) (Figure 2C, 2D). Anti-
mouse antibodies colocalized predominantly with Iba1 in
the soma and projections of microglial cells (Figure 2C).
Antibodies also colocalized with the oligodendroglial
marker p25 (Figure 2D), which indicates that α-syn-
Figure 2 Trafficking of AFF 1-induced antibodies into the CNS of MBP-α-syn tg mice. (A) Monoclonal AFF 1-induced antibodies were tagged
with Alexa-488 and administered to non-tg or MBP-α-syn mice. Alexa-488 tagged mAb-AFF 1 bounded α-syn within cell bodies (arrow-head) and
blood vessels (bv). As negative control, a non-immune Alexa-488-tagged IgG1 was used. Scale bar = 5 μm (B) mAb-AFF 1 or non-immune IgG1 were
tagged with Alexa-488 and administered to non-tg or MBP-α-syn mice. Time course analysis was performed every 24 h for 3 days, and fluorescence
was only increased in brain sections of MBP-α-syn tg animals injected with Alexa-488-tagged mAb-AFF 1. Results are shown as corrected intensity
values and expressed as average ± SEM. n = 3 animals per group and time point (C) AFF 1-induced antibodies were detected with and FITC-tagged
anti-mouse antibody in brain sections of immunized MBP-α-syn tg mice (green), together with an antibody against Iba1 (microglia) or S100 (astrocytes)
(red). Cell nuclei were stained with DAPI (blue). Colocalization was observed in microglial cell bodies and projections, but not in astroglial cells (arrows)
(D) AFF 1-induced antibodies detected with and FITC-tagged anti-mouse antibody in brain sections of immunized MBP-α-syn tg mice (green),
together with an antibody against p25 (oligodendrocytes) or NeuN (neurons) (red). Cell nuclei were stained with DAPI (blue). Colocalization was
observed in oligodendroglial cell bodies, but not in neurons (arrows). Scale bar = 5 μm.
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antibodies. We did not detected significant colocalization
with S100 (Figure 2C), suggesting that antibody-antigen
complexes are not significantly internalized by astrocytes.
Finally, neurons did not show anti-mouse antibody stain-
ing, as detected by double labeling with NeuN (Figure 2D).
This result is expected considering the fact that AFF
1-induced antibodies do not react with murine α-syn
(Figure 1A) [19].
Immunization with AFF 1 reduces the accumulation of
α-syn aggregates in MBP-α-syn tg mice
The α-syn burden was analyzed by immunostaining with an
anti-α-syn antibody in the areas most affected by the trans-
gene over-expression, such as the neocortex and striatum
(Figure 3A-C). A reduction in the number of α-syn positive
cells was observed with both the original α-syn antigen and
AFF 1 (Figure 3A), and quantitative analysis revealed a sig-
nificant reduction in the numbers of α-syn positive cells in
both areas following immunotherapy (Figure 3B, C). This re-
duction in the number of α-syn positive cells was not ac-
companied by an increase in the number of active caspase 3positive cells (Additional file 1: Figure S1), suggesting that
vaccination is not stimulating the apoptotic death of cells ac-
cumulating α-syn, but indeed reducing its accumulation.
Next, the effect of vaccination with AFFITOPEs® on
the levels of different α-syn species in the brain was de-
termined by immunoblot. Brain homogenates from
MBP-α-syn tg mice immunized with carrier/adjuvant
alone (vehicle), original α-syn antigen or AFF 1 were
assessed for the content of α-syn monomers and oligo-
mers using an antibody against human α-syn in both
soluble and insoluble fractions (Figure 3D-F). Only a
slight reduction was observed in the soluble levels of
monomeric α-syn (Figure 3D), but a significant reduc-
tion was observed in the levels of soluble oligomers
(Figure 3D,E). Analysis of the insoluble fraction showed
a statistically significant reduction of insoluble α-syn
species in the original α-syn antigen and AFF 1-
immunized MBP-α-syn tg mice compared to carrier/
adjuvant-treated animals (Figure 3D,F). These results
confirm that AFF 1 immunization induces antibodies
able to specifically bind to and reduce neurotoxic oligo-
meric/aggregated α-syn.
Figure 3 Immunization with AFF 1 reduces α-syn accumulation in MBP-α-syn tg mice. (A) α-syn immunoreactivity in neocortex and striatum of
non-tg and MBP-α-syn tg mice immunized with vehicle, original C-terminal α-syn antigen, or AFF 1 (B) Cell counts of α-syn-positive cells in neocortex (C) Cell
counts of α-syn-positive cells in striatum (D) Immunoblot analysis of total α-syn in the cytosolic and membrane fractions of protein extracts from non-tg and
MBP-α-syn tg mice immunized with vehicle, α-syn antigen, or AFF 1. Significant results of two mice per group are shown (E) Densitometric analysis of the
α-syn immunoreactive bands in the cytosolic fraction (F) Densitometric analysis of the α-syn immunoreactive bands in the membrane fraction. Results are
expressed as average ± SEM. (#) p < 0.05 when comparing vehicle-treated tg animals vs. immunized tg animals by one-way ANOVA with post hoc
Tukey-Kramer. For the vehicle-treated non-tg group, n = 5. For tg groups, n = 10 animals per group.
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in MBP-α-syn tg mice
In order to analyze if immunization with AFF 1 affects
neuroinflammation associated with α-syn accumulation,
immunohistochemical analysis of astrogliosis and micro-
gliosis was performed in MBP-α-syn tg mice treated
with vehicle, original α-syn antigen or AFF 1 (Figure 4)
using the astroglial marker GFAP and the microglial
marker Iba1. MBP-α-syn tg mice showed significant
astrogliosis and microgliosis when compared to non-tg
controls, observed as an apparent increase in the num-
ber of cell counts and intensity of the staining in stri-
atum (Figure 4A) and other areas such as hippocampus
and corpus callosum (not shown). However we did not
observe significant astroglial reactivity in the neocortex
of MBP-α-syn tg mice when compared to controls
(Figure 4A, B). Immunization with the original α-syn
antigen and with AFF 1 significantly reduced astroglial
cell counts in striatum to values similar to those ob-
served in non-tg animals (Figure 4C).
Microgliosis was also increased in the striatum of vehicle-
treated MBP-α-syn tg mice when compared to vehicle-
treated controls, but again not in neocortex (Figure 4D-F).Interestingly, it is worth noticing that MBP-α-syn tg ani-
mals do not usually display microgliosis at 10 months/old
[28], suggesting that the vehicle (carrier/adjuvant) in com-
bination with the tg phenotype (presence of extracellular α-
syn) could be the cause of the microgliosis observed in the
striatum of the MBP-α-syn tg animals. Immunization with
either the original α-syn antigen or AFF 1 increased micro-
glial cell counts when compared to vehicle-treated tg ani-
mals (Figure 4D, F), suggesting that microglial cells are
reacting to the presence of induced antibodies and/or
antibody-α-syn complexes. In this sense, it is worth noticing
that treatment with AFF 1 did not induce changes in micro-
glia cell counts in non-tg animals, indicating that AFF 1
induced antibodies are not inducing microgliosis by them-
selves but in the form of antibody-α-syn complexes.
Accumulation of α-syn in glial cells has been associated to
an increase in the expression of pro-inflammatory cytokines
[11], and AFF 1 has shown anti-inflammatory properties in
an animal model of PD by increasing anti-inflammatory
cytokine levels [19]. We analyzed the relative expression
levels of 40 cytokines and chemokines in the cytosolic
(soluble) fraction of non-tg mice and MBP-α-syn tg mice
treated with vehicle or AFF 1 using a mouse cytokine
Figure 4 Immunization with AFF 1 promotes microglial activation in MBP-α-syn tg mice. Non-tg mice or MBP-α-syn tg mice were immunized with
vehicle, original C-terminal α-syn antigen or AFF 1, and glial markers were analyzed by immunohistochemistry. (A) Immunostaining of the astroglial marker
GFAP in neocortex and striatum. Scale bar = 25 μm (B) Optical density quantification of GFAP staining in neocortex (C) Optical density quantification of GFAP
staining in striatum (D) Immunostaining of the microglial marker Iba1 in neocortex and striatum. Scale bar = 25 μm (E) Quantification of Iba1-positive cell
counts in neocortex (F) Quantification of Iba1 cell counts in striatum. Results are expressed as average± SEM. (*) p < 0.05 when comparing vehicle-treated
non-tg animals to tg groups by one-way ANOVA with post hoc Dunnett; (#) p < 0.05 when comparing vehicle-treated tg animals with immunized tg groups
by one-way ANOVA with post hoc Tukey-Kramer. For the non-tg group, animal numbers were n = 5 for vehicle and n= 3 for AFF 1. For tg groups, n = 10
animals per group.
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levels of cytokines and chemokines between non-tg and
MBP-α-syn tg mice (Figure 5), including a reduction in
levels of the anti-inflammatory cytokine IL-1Ra, IL-3 and
Interferon γ (IFNγ). IL-1Ra inhibits IL-1α and IL-1β pro-
inflammatory signaling by competing with them for receptor
binding [29], IL-3 has trophic factor functions in cholinergic
neurons [30], and IFNγ plays a dual role in inflammation
having both pro- and anti-inflammatory properties [31].
AFF 1 modulated cytokine and chemokine levels, inducing
an increase in IL-1Ra, IL-3 and IFNγ to levels similar to
non-tg animals. Levels of other cytokines such as GM-CSF
and IL-1α, which are traditionally associated with neuroin-
flammation, were not affected (Figure 5). These results fur-
ther confirm that immunization with AFF 1 modulates
neuroinflammation in MBP-α-syn tg mice.
Immunization with AFF 1 ameliorates the
neurodegenerative pathology in MBP-α-syn tg mice
Effects of AFF 1 immunization on synaptic and neurode-
generative pathology were also assessed in MBP-α-syn tg
mice. Sections from tg mice treated with vehicle, original
α-syn antigen or AFF 1 were immunostained with anti-
bodies against the dendritic marker MAP2, as well asthe neuronal marker NeuN (Figure 6A, D). MBP-α-syn tg
mice showed a significant decrease in MAP2 staining in
the neuropil of neocortex and striatum, which indicates
loss of dendritic arborization in these areas (Figure 6A-C).
Immunization with both the original α-syn epitope and
AFF 1 preserved from the loss of MAP2, and levels in im-
munized animals were similar to non-tg controls in the af-
fected areas (Figure 6B,C).
MBP-α-syn tg mice are also characterized by the pres-
ence of neuronal loss in neocortex and striatum, mea-
sured by a reduction in the number of NeuN-positive
cells in both areas (Figure 6D-F). This neurodegenera-
tion was also prevented by immunization with both the
original α-syn antigen and AFF 1 (Figure 6). Taken to-
gether, these results suggest that AFF 1-mediated α-syn
clearance is reducing synaptic pathology and neuronal
cell death.
Immunization with AFF 1 reduces demyelination and
motor behavioral deficits in MBP-α-syn tg mice
To examine the effect of active immunization with AFF 1
on myelination in the MBP-α-syn tg mice, sections were
stained with Luxol Fast Blue (LFB) and myelination was
analyzed in the neocortex and striatum (Figure 7A-C).
Figure 5 Immunization with AFF-1 modulates cytokine levels in MBP-α-syn tg mice. Cytokine levels in the cytosolic fraction of non-tg or
MBP-α-syn tg mice treated with vehicle or AFF 1 were analyzed using a proteomic array. Results are expressed as optical density relative to the
non-tg vehicle condition. (A) IL-1Ra (B) IL-3 (C) IFNγ (D) IL-1α (E) GM-CSF. Results are expressed as average ± SEM. (*) p < 0.05, (**) p < 0.01 when
comparing vehicle-treated non-tg animals with vehicle-treated tg animals by two-way ANOVA with post hoc Tukey. (#) p < 0.05, (##) p < 0.01
when comparing vehicle-treated tg animals with AFF 1-treated tg animals by two-way ANOVA with post hoc Tukey. n = 4 animals per group.
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MBP-α-syn tg mice display reduced levels of staining with
LFB in comparison to non-tg controls (Figure 7A), indica-
tive of myelin disruption in these mice. Immunization with
the original α-syn antigen or AFF 1 reduced demyelination,
observed as an increase in LFB staining in both neocortex
and striatum (Figure 7A) to values similar to non-tg con-
trols. This reduction in demyelination is likely consequence
of the reduction in oligodendroglial α-syn accumulation,
and subsequent restoration of myelin production.
Results were further confirmed by visualization of the
myelin sheath by electron microscopy in corpus callosum
(Figure 7D). In the non-tg mice, the myelin sheath can beobserved as a highly organized multilaminar structure
(Figure 7D). In the MBP-α-syn tg mice, these structures
are less numerous, have less layers and are substantially
more disorganized than in non-tg mice (Figure 7D-F). In
the MBP-α-syn tg mice immunized with the original α-
syn antigen or with AFF 1, the number of myelinated
axons as well as the number of myelin layers per axon
were preserved and their levels were comparable to non-
tg controls (Figure 7E, F). Therefore, it can be concluded
that active immunization with AFF 1 reduced demyelini-
zation in the MBP-α-syn tg mouse model of MSA.
In order to investigate if reduced demyelination was ac-
companied by behavioral improvements in the MBP-α-syn
Figure 6 Immunization with AFF 1 ameliorates the neurodegenerative pathology in MBP-α-syn tg mice. (A) Immunostaining for the synaptic
marker MAP2 (green) in the neocortex and striatum of non-tg mice or MBP-α-syn tg mice immunized with vehicle, original C-terminal α-syn antigen or
AFF 1. Cell nuclei were stained with DAPI (blue). Scale bar = 5 μm (B) Quantification of the percentage of the MAP2-positive area of neuropil in neocortex
(C) Quantification of the percentage of the MAP2-positive area of neuropil in striatum (D) Immunostaining for the neuronal marker NeuN in the neocortex
and striatum of non-tg mice or MBP-α-syn tg mice immunized with vehicle, original C-terminal α-syn antigen or AFF 1. Scale bar = 5 μm (E) Quantification
of NeuN-positive cell counts per 0.1 mm3 in neocortex (F) Quantification of NeuN-positive cell counts per 0.1 mm3 in striatum. Results are expressed as
average ± SEM. (*) p < 0.05 when comparing vehicle-treated non-tg animals to tg groups by one-way ANOVA with post hoc Dunnett; (#) p < 0.05 when
comparing vehicle-treated tg animals with immunized tg groups by one-way ANOVA with post hoc Tukey-Kramer. For the non-tg group, animal numbers
were n = 5 for vehicle and n = 3 for AFF 1. For tg groups, n = 10 animals per group.
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the round beam test to measure gait and balance impair-
ments (Figure 8A, B). Vehicle-treated MBP-α-syn tg mice
had a higher error rate (measured as foot slips/10 cm) than
vehicle-treated non-tg mice, indicative of balance impair-
ments in the tg animals (Figure 8A). AFF 1 treatment was
able to significantly decrease the number or errors made by
the MBP-α-syn tg mice (Figure 8A). However, the speed at
which the animals performed this task was not significantly
altered by the treatment (Figure 8B). Finally, the parkinson-
ian features have been related to the loss of dopaminergic
input to the basal ganglia [34]. In the MBP-α-syn tg mice
there is a loss of tyrosine hydroxylase (TH) immunoreactive
fibers in the striatum in comparison to the saline-treated
non-tg mice (Figure 8C). AFF 1 vaccination restored TH im-
munoreactivity in the MBP-α-syn tg mice to levels com-
parable with vehicle-treated non-tg mice (Figure 8C),
suggesting a protective effect of the treatment on dopa-
minergic fiber loss.
Immunization with AFF 1 increases microglial α-syn
clearance in MBP-α-syn tg mice
Finally, to determine which cell type is predominantly in-
volved in antibody-induced α-syn clearance in the MBP-α-syn tg mice, we analyzed the colocalization of neuronal and
glial markers with α-syn (Figure 9). As recently shown,
microglial cells have the ability to phagocytose α-syn and
clear out extracellular α-syn aggregates [35], and astrocytes
can also internalize α-syn [11,28]. In MBP-α-syn tg mice, α-
syn colocalized predominantly with oligodendrocytes (p25,
Figure 9C, D) and with astrocytes (S100, Figure 9E, F).
When MBP-α-syn tg mice were immunized with AFF 1
there was a reduction in the percentage of α-syn positive oli-
godendrocytes and astrocytes (Figure 9D, F) and an increase
in colocalization with microglia (Iba1, Figure 9A, B). Import-
antly, the number of p25-positive oligodendrocytes (25.6 ±
4.2 cells per field) did not change significantly in tg animals
after AFF 1 treatment. In a previous study we showed that
in MBP-α-syn mice there is propagation of α-syn from oli-
godendrocytes to astrocytes, and this result suggests that
immunotherapy with AFF 1 reduced the extracellular trans-
fer of α-syn to astroglia. Furthermore, the increase in α-syn-
positive microglial cells suggests that immunization with
AFFITOPEs® is also stimulating the clearance of α-syn by
microglial cells. Neurons (NeuN, Figure 9G, H) did not
show α-syn staining under any condition.
In conclusion, active immunization with AFF 1 re-
duces the accumulation of α-syn in oligodendrocytes
Figure 7 Immunization with AFF 1 reduces demyelination in MBP-α-syn tg mice. (A) LFB staining of myelin in the neocortex (and corpus callosum)
and striatum of non-tg mice or MBP-α-syn tg mice immunized with vehicle, original C-terminal α-syn antigen or AFF 1. Scale bar = 250 μm (B) Quantification
of LFB staining by optical density in neocortex (C) Quantification of LFB staining by optical density in striatum (D) Electron microscopy images of myelin
sheaths in the corpus callosum of non-tg mice or MBP-α-syn tg mice immunized either with vehicle, α-syn antigen or AFF 1. Representative images taken
with the transmission electron microscope (TEM) are shown at low magnification (5,000x) and high magnification (25,000x). Scale bars = 2.5 μm and 500 nm.
vac, vacuola (E) Quantification of the number of myelinated axons in corpus callosum (F) Quantification of the average number of myelin layers per axon in
corpus callosum. Results are expressed as average ± SEM. (*) p < 0.05 when comparing vehicle-treated non-tg animals to tg groups by one-way ANOVA with
post hoc Dunnett; (#) p < 0.05 when comparing vehicle-treated tg animals with immunized tg groups by one-way ANOVA with post hoc Tukey-Kramer. For
the non-tg group, animal numbers were n = 5 for vehicle and n= 3 for AFF 1. For tg groups, n = 10 animals per group.
Figure 8 Immunization with AFF 1 reduces behavioral impairments and TH alterations in MBP-α-syn tg mice. (A) Performance in the
transversal round beam test, measured as slips per 10 cm in non-tg or MBP-α-syn tg mice immunized with vehicle or AFF 1 (B) Speed of the
animals in the transversal round beam test, measured as cm per second in non-tg or MBP-α-syn tg mice immunized with vehicle or AFF 1 (C)
Quantification of TH staining by optical density in striatum. Results are expressed as average ± SEM. (*) p < 0.05 when comparing vehicle-treated non-tg
animals to vehicle-treated tg animals by one-way ANOVA with post hoc Dunnett; (#) p < 0.05 when comparing vehicle-treated tg animals with AFF 1-treated
tg animals by one-way ANOVA with post hoc Tukey-Kramer. For the non-tg group, animal numbers were n = 5 for vehicle and n = 3 for AFF 1. For tg groups,
n = 10 animals per group.
Mandler et al. Molecular Neurodegeneration  (2015) 10:10 Page 9 of 15
Figure 9 Immunization with AFF 1 increases microglial α-syn clearance in MBP-α-syn tg mice. (A) Double immunostaining for the microglial marker
Iba1 (red) and α-syn (green) in vehicle- and AFF 1-immunized MBP-α-syn tg mice. The location of Iba1-positive cells is denoted by arrows and the location
of α-syn-positive cells by asterisks. Cell nuclei were stained with DAPI (blue). Scale bar = 10 μm. (B) Quantification of the percentage of colocalization between
Iba1 and α-syn (C) Double immunostaining for the oligodendroglial marker p25 (red) and α-syn (green) in vehicle- and AFF 1-immunized MBP-α-syn tg mice.
The location of p25-positive cells is denoted by arrows. Cell nuclei were stained with DAPI (blue). Scale bar = 10 μm. (D) Quantification of the percentage of
colocalization between p25 and α-syn (E) Double immunostaining for the astroglial marker S100 (red) and α-syn (green) in vehicle- and AFF 1-immunized
MBP-α-syn tg mice. The location of S100-positive cells is denoted by arrows and the location of α-syn-positive cells by asterisks. Cell nuclei were stained with
DAPI (blue). Scale bar = 10 μm. (F) Quantification of the percentage of colocalization between S100 and α-syn (G) Double immunostaining for the neuronal
marker NeuN (red) and α-syn (green) in vehicle- and AFF 1-immunized MBP-α-syn tg mice. Cell nuclei were stained with DAPI (blue). Scale bar = 5 μm.
(H) Quantification of the percentage of colocalization between NeuN and α-syn. Results are expressed as average ± SEM. (*) p < 0.05 when comparing
vehicle-treated tg animals with AFF 1-treated tg animals by Student’s t-test. n = 10 animals per group.
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neurodegenerative pathology in the MBP-α-syn tg mice,
an animal model of MSA.
Discussion
The present study showed that immunization with the
AFFITOPE® vaccine AFF 1 reduced propagation and ac-
cumulation of α-syn, demyelination, motor deficits and
neurodegeneration in a tg mouse model of MSA. AFF 1
was selected for this study because it had previously
demonstrated a high ability to elicit α-syn specific anti-
bodies and to ameliorate behavioral and neurodegenera-
tive pathology in two models of synucleinopathies [19].
Furthermore, AFF 1 elicits the generation of antibodies
that do not cross-react with other members of the synu-
clein family, and does so without promoting α-syn spe-
cific T-cell responses [19]. This approach allows for the
generation of long term, specific responses suitable for
the treatment of synucleinopathies such as MSA.
Active and passive immunization studies have previously
shown that immunization reduces the pathology in α-syn tg
models of PD. Active immunization of PDGF-α-syn mice
with full-length human α-syn induces the production of
high affinity antibodies, together with a decrease in neuronalα-syn accumulation and neurodegeneration [20]. Further-
more, vaccination is also effective experimentally in other
mouse models of neurodegenerative diseases, by reducing
the accumulation of toxic proteins aggregates such as amyl-
oid β [36-39], tau [40,41], prion protein [42] and huntingtin
[43,44]. Interestingly, the antibodies produced by mice
immunized with full-length human α-syn recognized epi-
topes within the C-terminal region of human α-syn [20].
Passive immunization studies with antibodies against the C-
terminus of α-syn further confirmed this observation [21].
Epitope mapping of AFF 1-induced antibodies shows that
the antibodies generated also recognize an area in the C-
terminal region of α-syn (110–130) [19], supporting the in-
volvement of this part of the protein in antibody-mediated
targeting and clearance. Interestingly, here we report that
AFF 1 vaccination also reduced α-syn spreading from oligo-
dendrocytes to astroglia. This finding confirms previous
passive immunization studies showing that antibodies
against the C-terminus of α-syn also reduced α-syn propa-
gation [45]. Furthermore, this is the first observation that
propagation between glial cells can be halted by active
immunization. Propagation of α-syn from oligodendro-
cytes to astroglia has been previously described in the
MBP-α-syn mice [28], and although its relevance in MSA
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dendrocytes do express α-syn in the MSA brain [10] sug-
gests that this type of propagation could be also happening
in MSA. Moreover, reducing propagation of α-syn from oli-
godendrocytes to astroglia might also prevent neuroinflam-
matory responses derived from the accumulation of α-syn
within astrocytes [11-13]. However, a more detailed analysis
of neuroinflammation after immunization with AFF 1 in
MBP-α-syn tg mice is needed to elucidate the protective ef-
fect of AFF 1 against inflammation in MSA.
First studies on active vaccination against α-syn were per-
formed using full-length human α-syn in the mThy1-α-syn
tg model of dementia with Lewy bodies [20]. In this model,
active vaccination with human α-syn decreased accumula-
tion of aggregated α-syn in neuronal cell bodies and synap-
ses and reduced neurodegeneration. Antibodies produced
by immunized mice recognized abnormal α-syn associated
with the neuronal membrane and promoted the degradation
of α-syn via lysosomal pathways [20,46]. In the present study
we did not observe α-syn or antibody reactivity within neu-
rons, this result suggesting that antibodies elicited by AFF 1
do not recognize murine α-syn, which is expressed pre-
dominantly by neurons, and that neurons do not play a sig-
nificant role in clearing extracellular human α-syn in the
MBP-α-syn tg model of MSA. Furthermore, AFF 1 has
been previously assessed in an immunization protocol of
two different tg mouse models of synucleinopathies, the
PDGF-α-syn and the mThy1-α-syn tg mice [19]. Vaccin-
ation with AFF 1 in those animals resulted in high antibody
titers that crossed into the CNS and recognized α-syn ag-
gregates, similar to the results obtained in MBP-α-syn tg
mice. Interestingly in those models clearance of α-syn also
involved activation of microglia and increased anti-
inflammatory cytokine expression [19]. In this sense and
similarly to what we observed in the MBP-α-syn tg mice,
AFF 1 also induced an increase the levels of anti-
inflammatory cytokines such as IL-1Ra in the PDGF-α-syn
tg mouse model of PD [19]. These results combined
suggest that the clearance mechanism of extracellular
antibody-antigen complexes is probably common to all
synucleinopathies. The mechanism through which the anti-
bodies are internalized is not completely understood, but
might include interaction with Fcγ receptors [27] and endo-
lysosomal trafficking for autophagy degradation [20].
However, we also observed internalization of antibodies in
α-syn-expressing oligodendrocytes in the MBP-α-syn tg
mice, suggesting that these cells can also uptake antibody-
antigen complexes or that their membrane integrity is com-
promised and antibodies can access intracellular α-syn de-
posits. Finally, other clearance mechanisms such as clearing
α-syn into the venous system or via other glial mechanisms
have not been evaluated and therefore cannot be ruled out.
Also of interest is the fact that immunization with
AFF 1 prevented myelin loss and reduced motor deficitsin the MBP-α-syn tg mice. MBP-α-syn tg animals show
significant myelin pallor in white matter tracts [32], simi-
lar to the demyelination observed in the MSA brain [47].
The protective effect of immunotherapy on myelination is
probably a consequence of the reduction in α-syn accu-
mulation within oligodendrocytes and/or the reduction in
α-syn propagation. Moreover, a direct protective effect of
the treatment on myelin integrity cannot be excluded ei-
ther. Interestingly, this protective effect on myelination
has never been reported in active immunization studies
for synucleinopathies, and it is a very good indicator of
the effects of the AFFITOPE® on the preservation of the
brain structure in MSA.
Finally, it is important to consider that MBP-α-syn tg
animals over-express human α-syn directly in oligoden-
drocytes, therefore not showing α-syn propagation from
neurons to oligodendrocytes, which it has been reported
to occur in MSA patients [48-50]. In this case, AFF 1-
induced antibodies might also be beneficial in halting α-
syn transmission from neurons [19], which is likely an
early event in MSA progression. Moreover, as AFF 1-
induced antibodies are specific to human α-syn, the
question remains to if they could interact and block the
physiological activity of this protein. In this sense, it
must be noted that in healthy individuals α-syn should
not be present in the extracellular space or bound to the
plasma membrane, where the interaction with the anti-
bodies might take place. However, in MSA patients AFF
1-induced antibodies could interact with extracellular or
membrane-bound oligomeric α-syn, which are key fea-
tures of the disease pathology [51]. Therefore, binding of
AFF 1-induced antibodies to intracellular, physiological
human α-syn is not expected. In this regard, AFF 1 is
currently being studied in clinical phase I studies in pa-
tients with early MSA.
Conclusions
In conclusion, targeting extracellular α-syn with active
immunotherapy using the AFFITOPE® AFF 1 reduced α-
syn accumulation within oligodendrocytes, prevented α-
syn spreading and protected myelination in a tg mouse
model of MSA. Microglia uptake of antibody antigen
complexes is suggested as the clearance mechanism fol-
lowing immunization. Finally, Phase 1 testing is currently
in preparation for two AFFITOPE® vaccines that target α-
syn using MSA as a model for synucleinopathies.
Methods
Generation of AFF 1
The AFFITOPE® AFF 1 was generated and selected as previ-
ously described [19]. Briefly, AFF 1 was synthesized by
FMOC solid phase peptide synthesis (EMC microcollections
GmbH) conjugated to the carrier protein KLH (Biosyn
GmbH) using N-gamma-Maleimidobutyryl-oxysuccinimide
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cysteine residue. AFF 1-KLH conjugates were adsorbed to
alhydrogel as adjuvant. The dose used for vaccinating the
animals was 30 μg of peptide containing 0.1% alhydrogel.
Treatment of animals and antibody titers
Mice expressing human α-syn under the control of the
Myelin Basic Protein (MBP) promoter (MBP-α-syn tg) were
generated as previously described [32]. In this study we
used the MBP1 line, as animals express an intermediate
level of α-syn compared to the other lines and they are
more viable and less aggressive. MBP-α-syn tg mice de-
velop progressive accumulation of α-syn inclusions in oligo-
dendrocytes along the axonal tracts in the brainstem, basal
ganglia, cerebellum, corpus callosum, and neocortex, lead-
ing to neurodegeneration in the neocortex and to loss of
dopaminergic fibers in the basal ganglia. MBP-α-syn tg
mice were treated with the original α-syn antigen or AFF 1
plus carrier/adjuvant or carrier/adjuvant alone (n = 10/
group). For the non-tg mice, animal numbers were n = 5
for the vehicle-treated group and n = 3 for the AFF 1-
treated group. Treatment started when mice were 4–5
months of age, 6 injections were delivered subcutaneously
at monthly intervals, and plasma collection was performed
two weeks after each injection. Treatment was well toler-
ated, and no weight loss or other complications were noted.
All mice were between 10–11 months of age by the end of
the study. All experiments were carried out in accordance
with the guidelines laid down by the NIH regarding the
care and use of animals for experimental procedures.
Plasma samples from individual animals (n = 10 per con-
dition), obtained two weeks after the third immunization,
were subjected to ELISA analysis to measure the titers of
antibodies induced by repeated immunization. Substrates
used included recombinant human α-syn and β-synuclein
(2 μg/ml, rPeptide) and the AFF 1 peptide (EMC microcol-
lections GmbH). The peptides were used as bovine serum
albumin (BSA) conjugates (1 μM). Optical density (OD)
was measured at 405 nm using a microwell plate reader
(Tecan, Switzerland), and titers were expressed as ODmax/
2 values.
Isolation of AFF 1-induced antibodies and labeling
The AFF 1-induced monoclonal antibody (mAb)-AFF 1
(mouse IgG1) directed against α-syn was isolated and la-
belled with Alexa-488 as previously described [26]. Briefly,
BALB/c mice were repeatedly immunized with AFF 1 conju-
gate vaccine using alhydrogel as adjuvant [26]. Fusion of
spleen cells with Ag8.531 myeloma cells and cloning of the
hybridoma was performed as previously described [52].
mAb-AFF 1 was purified using a Protein G-sepharose col-
umn (HiTrap Sepharose, GE Healthcare) and labelled with
Alexa-488 using Alexa Fluor® 488 Protein Labeling Kit (Life
Technologies) according to manufacturer’s protocol. Forstudies of antibody trafficking into the CNS, 6 month-old
non-tg and MBP-α-syn tg mice (n = 24/group) were injected
intravenously with the Alexa-488-labeled mAb-AFF 1, or a
non-immune control Alexa-488-tagged IgG1 at a concentra-
tion of 1 mg/kg. Mice were sacrificed at 0, 24, 48 and 72 h
after injection (n = 3/group and time point).
Behavioral testing
MSA is characterized by motor abnormalities such as
tremor, rigidity and gait and limb ataxia, and many of
these features are replicated in the MBP-α-syn tg mice
[32] and reflected in their performance in the round beam
test [33]. The round beam test allows for the assessment
of gait and balance impairments through distance traveled
in an allotted amount of time over a round beam placed
horizontally. As previously described [53], three consecu-
tive trials, 1 min each, were run in one day. The total for-
ward distance traveled and the numbers of foot slippages
were recorded. Speed on the beam was calculated as dis-
tance traveled/time, and errors on the beam were calcu-
lated as foot slips/distance traveled.
Immunoblot analysis
Hemibrains were homogenized and divided into cytosolic
and membrane fractions as previously described [54,55].
For immunoblot analysis, 20 μg of total protein per lane
was loaded on 4-12% Bis-Tris SDS-PAGE gels and blotted
onto polyvinylidene fluoride membranes. To determine
the effects of the immunotherapy in levels of α-syn, blot-
ted samples from immunized α-syn tg mice were probed
with antibodies against full length human α-syn (1:1000,
SYN211, Life Technologies). Incubation with primary
antibody was followed by species-appropriate incubation
with secondary antibody tagged with horseradish peroxid-
ase (1:5000, Santa Cruz Biotechnology), visualization with
enhanced chemiluminescence, and analysis with a Versa-
doc XL imaging apparatus (BioRad). Analysis of β-actin
(Sigma) levels was used as a loading control.
For studying which species the antibodies elicited by AFF
1 recognize, recombinant or 4-hydroxy-2-nonenal-treated
α-syn [25] were loaded on 4-12% Bis-Tris SDS-PAGE gels
and analyzed by immunoblot using AFF 1-elicited antibodies
as primary antibody. The monoclonal antibody LB509 (Cov-
ance) served as positive control.
Mouse cytokine array
400 μg of protein from the cytosolic fraction of brain tis-
sue homogenates (n = 4 per condition) were used for
analyzing relative levels of 40 different mouse cytokines
using a Mouse cytokine panel array (R&D) following the
instructions of the supplier. Briefly, tissue homogenates
were diluted and mixed with a cocktail of biotinylated
detection antibodies. The mixtures were then incubated
with nitrocellulose membranes where capture antibodies
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HRP and chemiluminiscent detection reagents were then
added sequentially, and the binding of the detection
antibody was detected in a VersaDoc gel-imaging ma-
chine (BioRad) and quantified using Quantity One soft-
ware (BioRad).
Immunohistochemistry and electron microscopy
At the end of the vaccination protocol, animals were
transcardially perfused with physiological saline and brains
were collected. Brains were divided sagitally into right and
left hemibrains. The left hemibrain was fixed in 4% para-
formaldehyde in phosphate buffered saline and serially
sectioned in the vibratome, and the right hemibrain was
snap-frozen and stored at -80C for subsequent protein ex-
traction. The right hemibrain was serially sectioned with
the vibratome at 40 μm and stored at -20C in cryoprotec-
tive medium. Sections were immunostained with anti-
bodies against α-syn (Chemicon, 1:250), NeuN (neuronal
marker, Millipore, 1:1000), MAP2 (dendrites, Millipore,
1:250), GFAP (astroglial marker, Millipore, 1:500), Iba1
(microglia, Wako, 1:2000), p25 (oligodendrocytes), and
horse anti-mouse IgG (Vector Laboratories) and imaged
with an Olympus BX54 bright field digital microscope or
a laser scanning confocal microscope. For determination
of reactivity against α-syn deposits in situ, plasma from
AFF 1-vaccinated tg animals was used (dilution 1:100) to
stain sections from mThy1-α-syn transgenic and MBP-α-
syn transgenic mice. Digital images were analyzed with
the ImageQuant 1.43 program (NIH) to determine num-
bers of α-syn aggregates, dendrites, neurons, astrogliosis
and microgliosis [27,33,53]. A minimum of 100 cells was
counted per animal and field and counts are expressed as
the average number of positive cells per field (230 μm x
184 μm). Stereological analysis of NeuN immunoreactivity
was conducted by the dissector method using the Stereo-
Investigator System (MBF Bioscience), and the results
were normalized to provide cell density information and
expressed as cell counts per 0.1 mm3. Additional sections
were stained with LFB in order to visualize the myelin
layers and imaged on the Olympus BX54 brightfield digital
microscope. Quantification of LFB staining was performed
by obtaining optical density measurements using the Ima-
geQuant software and corrected against background signal
levels. Optical density is expressed in arbitrary units. For
% area quantifications, threshold values were set to exclu-
sively select neuropil staining and the percentage of the
total area was quantified.
For electron microscopy, vibratome sections were post-
fixed in 1% glutaraldehyde, treated with osmium tetraox-
ide, embedded in epon araldite and sectioned with the
ultramicrotome (Leica). Grids were analyzed with a Zeiss
OM 10 electron microscope as previously described [21].
Cells were randomly acquired from 3 grids, and electronmicrographs were obtained at a magnification of 5,000X
and 25,000X. The number of myelinated axons and mye-
lin layers were quantified in corpus callosum in areas of
similar axon size.
Double immunolabeling
To determine the colocalization between α-syn and
neuronal (NeuN) and glial markers (Iba1, S100, p25),
double-labeling experiments were performed as previ-
ously described [28]. Vibratome sections were immuno-
labeled with antibodies against S100 (astroglia, Sigma,
1:250), Iba1 (microglia), p25 (oligodendrocytes) or
NeuN (neurons), and the immunoreactive structures
were detected with the Tyramide Signal Amplification™-
Direct system (1:100, NEN Life Sciences), while α-syn
was detected with an antibody specific for human α-syn
(SYN211, Sigma, 1:250) and a FITC-tagged secondary
antibody (Vector Laboratories, 1:75). Cell nuclei were
stained using ProLong® Gold Antifade Mountant with DAPI
(4′,6-diamidino-2-phenylindole) (Molecular Probes). Sec-
tions were imaged with a Zeiss 63X objective on an Axiovert
35 microscope (Zeiss) with an attached MRC1024 laser
scanning confocal microscope (BioRad) [56].
Statistical analysis
Values are expressed as average ± standard error of the
mean (SEM). To determine the statistical significance we
used one-way analysis of variance (ANOVA) with post-hoc
Dunnett test when comparing to the control condition.
Additional comparisons were done using Tukey-Kramer
post hoc test. For Figure 5, we used two-way ANOVA with
post-hoc Tukey. For comparing two groups, Student’s t-test
was utilized. The differences were considered to be signifi-
cant if p values were less than 0.05.
Additional file
Additional file 1: Figure S1. Immunization with AFF 1 does not affect
active caspase 3 levels in MBP-α-syn tg mice. Double immunostaining for
active caspase 3 (Abcam antibody) (red) and α-syn (green) in vehicle- and AFF
1-immunized MBP-α-syn tg mice. Cell nuclei were stained with DAPI (blue).
Negative and positive controls included sections from non-tg naïve mice and
from mice treated with kainic acid (not shown). Scale bar = 15 μm.
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